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Failing to adapt – the ageing immune system’s role
in cancer pathogenesis
Christopher M Jones
School of Clinical & Experimental Medicine, University of Birmingham, UK
Summary
A person’s risk of developing cancer rises exponentially
with age, an increase that is widely considered to result
from cumulative exposure tomutagenic agents. However,
cancer incidence rates decelerate and plateau beyond
85 years of age and numerous malignant pathologies
peak in incidence during early or middle life, indicating
an important role for additional factors in controlling
the timing and nature of cancer development. Given
that immune function is known to decrease with age,
malignant neoplastic change may be induced by increased
chronic infection and the onset of a pervasive low grade
inflammatory environment. This article discusses in detail
the ageing immune system’s role in cancer pathogenesis
and demonstrates that key polymorphisms coding for
relatively low pro-inflammatory cytokine production act
to protect some populations from age-induced neoplastic
transformation.
Key words: ageing, cancer, immunosenescence, inflam-
mation, neoplasms.
Introduction
From age 30, the population of the UK, and
indeed the wider western world, experiences
an exponential increase in the incidence of
malignant neoplastic pathology (discussed herein
as cancer).1–6 In contrast, immunity appears to
decline with age and low-level chronic inflam-
mation becomes commonplace.7,8 Interestingly,
however, cancer incidence rates begin to decelerate
and plateau at age 85,5 and rates of diagnosis
of a number of cancers peak many years before.
Incidence rates of testicular cancer, for example,
are greatest between the ages of 25 and 35, falling
thereafter, whilst male bowel cancer incidence
rates fall throughout the ninth decade of life.1–4
These exceptions to the rule, coupled with the
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relatively low rates of cancer presentation amongst
centenarians,9 provide evidence to suggest that
increased exposure to mutagenic agents does not
reasonably explain cancer incidence rates in all
cases.
It is perhaps confusing then that cancer
is frequently discussed as resulting from an
accumulation of genetic change as a means of
explaining the rise in incidence of this disease with
increasing age.10 Whilst this article will not contest
this long-established viewpoint, it will argue that
the plateau of cancer incidence rates starting from
85 years of age, coupledwith low cancer prevalence
in centenarians, indicates that another factor –
the immune system – must play a role in age-
related cancer pathogenesis. It will further be
argued that polymorphisms in genes controlling
cytokine production within a set few population
groups provide a crucial evolutionary advantage
and evidence of adaptation to longer life that is
significantly beyond that of the general population.
The role of the extracellular environment in
cancer pathogenesis
Cancer is noted most predominantly as a
devastating condition of ageing, with increasing
age allowing for further exposure to mutagenic
insults.11 In order for a cell to be regarded as
cancerous it must commonly possess limitless
replicative potential, a lack of response to growth
inhibitory signals, an ability to evade apoptosis
and a tendency to invade tissues and metastasise.
Furthermore, cancer is regarded as a disease of
increasing genetic instability, and is thus associated
with a multi-step pathogenesis through which no
one insult can induce the disease alone.11 Many
cells adopt these changes, although only cancers
that form in solid tissues (and not haematological
cancers) will be discussed.
Importantly, the genetic makeup of cancerous
cells, and their precursors, is influenced by the
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environment in which they reside. Kuperwasser
et al.12 have, for instance, elegantly highlighted
that seemingly normal epithelial cells from breast
tissue can be altered to grow in a malignant
fashion under variant extracellular conditions.
This, and important work published by Bissell
et al.13 in 2003 (which discovered that it was
possible to revert malignant breast epithelium
back to non-malignant epithelium under differing
tissue conditions) have reignited interest in the
susceptibility of cancer cells to change induced by
their immediate environment.
In their 2004 paper, Schwartsburd et al.14
termed this environment the ‘cancer-supportive
microenvironment’ (CM) or the ‘pro-cancer
microenvironment’ (PCM), depending on the
level of instability of the cells in question.
The importance of this microenvironment is
emphasized further by evidence indicating that
cancer cells will only continue to proliferate within
a CM,15 and that some cancer cells actively
secrete factors to ensure that their extracellular
environment is supportive to their growth.16 It
is consequently appropriate to state that, as part
of the multistep pathogenesis model of cancer,
mutagenic insults (whether germline or somatic)
contribute to the onset of malignant disease but
that the age at which such cancers develop and their
behaviour upon presentation is ultimately likely to
be related to their CM, which is directly under the
control of the immune system.
One can thus hypothesize that the ageing
immune system, in failing to protect from the
pathogenic causative agents of some cancers
(resulting in localized inflammation),7,17 and
by aberrantly initiating generalized chronic
inflammation,18 plays a role in modulating the
extracellular environment to create a PCM/CM.
This, one theorizes, is likely to explain why
centenarians often escape cancer despite living
longer and why incidence rates for malignant
neoplastic pathologies fail to correlate completely
with exposure time to potential mutagenic agents.
Immunosenescence
The generalized immune dysfunction seen with
increasing age is commonly termed ‘immuno-
senescence’ and encompasses a complex array of
changes in all aspects of the immune system.19,20
Many of these changes lead to an increased
susceptibility to infection, whilst several more lead
to a state of chronic, low-grade inflammation
(often termed ‘inflammaging’),17,21–27 although
both such forms of immune system change are
inexorably linked.28
It is likely, particularly in the light of the
molecular change accompanying the ageing of an
individual, that all cells of the immune system
are affected by ageing,29 although there are many
contradictory reports concerning the precise fate of
its various components.8,14,18–21,26–28 Much of this
debate centres on the interplay between innate and
adaptive immunity, focusing on how changes in the
cellular components of the innate immune system
are able to influence overall immune function.
The ageing innate immune system
Dendritic cells (DCs), for example, are vital to
the immune system’s ability to recognize and
respond to antigen, but their capacity to migrate to
infective sites and phagocytose potential antigen is
thought to be impaired in older people.30 Research
attempting to clarify this hypothesis has been
relatively unproductive, however, as it remains
unclear as to whether this impairment is due to an
inherent problem with the DC itself (as suggested
by Araki et al.,31 Clague et al.32 and Del Prete
et al.33) or with declining numbers of DCs in old
age.34
Various research groups have identified poten-
tially raised in vivo neutrophil infiltrate in aged
individuals when compared with their younger
counterparts (Gomez et al.41,42 and Swift et al.,43
amongst others). Yet, apoptosis in these cells
during inflammation is reported to occur more
readily with increasing age in vitro,44–46 thought to
be due to defects in the B-cell lymphoma-2 (Bcl-2)
apoptosis regulator protein and the Janus kinase-
signal transducer and activator of transcription
(JAK-STAT) pathway.45,46 This latter finding,
coupled with evidence of poorer phagocytosis and
respiratory burst action,47,48 indicates declining
neutrophil functionwith age partially compensated
for by increased bone marrow production.
Eosinophils (acid-staining granulocytes with
similar polymorphic nuclei to neutrophils) are vital
in the response to parasitic infection but also play a
significant role in mediating type 1 hypersensitivity
reactions. Asthma is one such reaction and whilst
patients with this condition are defined by a
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constant eosinophilia throughout life,49 increased
morbidity and mortality in later life indicates
declining eosinophil functionwith increasing age.50
The eosinophil blood count of healthy individuals
has, however, been shown to increase with age (and
intriguingly in parallel with IL-6 concentration,51
raising suggestions of a role for eosinophils in
modulating age-related IL-6 levels), supporting the
rise seen with neutrophils.
Basophils, and the mast cells these granulocytes
give rise to, have failed thus far to demonstrate
an overall increase or decrease with age.29 It is
important to note that the significant distribution
of mast cells amongst many different tissue types
is likely to be responsible for presenting this
confusing picture. It is thought, however, that both
the number and the effector function of mast cells
increases with age; potentially underlying, at least
in part, the process of inflammaging.14
Macrophages (mononuclear cells derived from
monocytes) typically secrete a raft of pro-
inflammatory cytokines when activated. In
vitro evidence appears to indicate decreased
cytokine production in some populations of
older macrophages.52–54 This can be regarded
as particularly surprising in the context of
inflammaging, and in vivo evidence points towards
an overall increase, rather than decrease, in
cytokine production.55 Exciting new research
has, on the other hand, demonstrated decreased
tumour necrosis factor-α (TNF-α) production
by cutaneous macrophages in older people,54
supporting the former assertion. The apparent
decline in macrophage function with increasing age
is supported by findings that indicate decreased
phagocytic macrophages in older adults in the face
of a potentially increased progenitor number.56
Macrophages, much like mast cells, reside in
multiple different tissues and an examination of
their changes with age is confounded as a result.53
It is thus hypothesized that although their response
to acute infection is poorer,52–54 macrophages
in ageing individuals chronically secrete low but
pathological levels of cytokines.53
More conclusive change is offered by natural
killer (NK) and NKT cells, however, with
circulating numbers of both cellular populations
increasing in older individuals.55,57 Changes in NK
cell number are possibly (though a mechanism
is yet to be elucidated) a compensatory response
to the age-related decline in the cytotoxic-
killing function of these cells.57 The obvious
consequence of such a change is an apparent
decrease in the body’s ability to fight off viral
infection with increasing age, but little research
has been conducted with a view to identifying the
contribution of NKT cells to immunosenescence.
The ageing adaptive immune system
Many of the changes noted as occurring in the
adaptive immune system during ageing are likely to
arise as a result of differences in the innate immune
system. Of crucial importance is the process of
thymic involution that occurs with increasing age.
Evidence from mouse models, and more recently
in vivo human studies, has further enhanced our
understanding of this process.58 Fascinatingly, the
thymus is still active in later life (though at a
much decreased level to very early life), despite the
process of involution potentially starting during
early childhood.59 Unsurprisingly, this decreased
activity significantly impacts on T-cell and B-cell
lymphopoiesis.
The relative lymphopenia seen in ageing is
accentuated by increasingly impaired lymphocyte
function overall. One such change, the age-related
expansion of antigen-specific CD8+ (and to a
lesser extent CD4+) T-cells,60 is exceptionally
well characterized and exceedingly interesting (it
may potentially also occur in B-cells, but this
is less well characterized).60 It is thought that
this expansion, of T-cells specific for previously
encountered antigen, results in a T-cell population
primed predominantly for a set few antigenic
determinants and unable to rapidly adapt and
respond to newly exposed pathogens.Mature naı¨ve
T-cells also require ‘niche’ sites on which they
may encounter antigen, but a large population
of antigen-specific T-cells is likely to inhibit their
ability to reside on these sites and respond to new
antigen.61
T-regulatory cells (Tregs) have also been the
subject of much attention from immunologists and
gerontologists. Lages et al.62 in 2008 illustrated
the more suppressive nature of Tregs in older
individuals when compared with their younger
counterparts, hypothesizing (and supporting with
in vitro findings) that these cells stifle T-lymphocyte
function in older individuals and thus allow for
the reactivation of chronic infections. Other studies
have supported these findings with evidence of age-
related in vivo increases in Treg cell number.54
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Interlinked ageing
The changes discussed thus far have been noted
in a very linear fashion but the immune system
is exceptionally dynamic, with cells providing
constant feedback to one another through secreted
factors and direct contact. The result is that no
one change occurs without affecting another and
that cells of the immune system age as a whole,
rather than independently of one another. It is
also apparent that contrasting research findings
present a confusing picture of the aged immune
system. Whilst cancer is the subject of this article,
ageing carries further significant consequences.
Older individuals suffer from increases in both
the number and the severity of acute infections
for example, and chronic infections are known to
be re-activated as we age.62 An example of this is
the varicella-zoster virus, which re-activates and
causes shingles in a significant number of older
people. More relevant to cancer, however, are
pathogenic agents capable of causing deleterious
chronic infection.
Pathogen infection and tumour
immunosurveillance
The bacterium Helicobacter pylori, and its
counterparts human papilloma virus (HPV),
hepatitis C virus (HCV) and hepatitis B
virus (HBV) amongst many others, have been
associated with evading the immune response
and causing persistent infection as a result. The
outcome of this continual pathogenic presence
and the corresponding unrelenting infection is
an uncontrolled and undesirable inflammatory
response, thought to be largely responsible for
the neoplastic transformation induced by these
pathogens.14,40 Whilst this change corresponds
well with that induced through the immune system
itself in inflammaging, it is exciting to identify
how immunosenescence impacts on the immune
system’s inability to clear harmful bacteria and
viruses that may progress to cause malignant
neoplastic disease.
It is important to note that a significant
proportion of older people may have initially been
exposed to a pathogen (that has since unrelentingly
infected them) in the early stages of their life.
Although the ageing immune system is thus not
at fault in terms of the ease at which they are
infected, its changing characteristics with age, such
as the increase in specific CD4+ and CD8+ T-cells,
will affect the potential for carcinogenesis. During
ageing, for example, oligoclonal expansion of a
T-lymphocyte population specific for the pathogen
will lead to a greater inflammatory response against
it. Furthermore, pathogen reawakening, occurring
as a result of immunosenescence, is likely to cause
further damage.
Faced with the presence of H. pylori, it is
unlikely that the DCs of an aged individual would
begin to present antigen and trigger an immune
response as effectively as in a younger individual,
allowing the bacterium to infect the host.
Macrophages in the skin, as has been discussed,
would also be limited in their antimicrobial
response and research has demonstrated a
weakening of their nitric oxide (NO) production.31
NO release, one of the most effective anti-
H. pylori responses, is often, but not always,
down-regulated by H. pylori,39,40 allowing the
bacterium to survive within the host. The reduction
in NO production with age is, therefore, likely to
uniformly eradicate this effective anti-microbial
response. As previously stated, Treg activity also
increases with age,62 and the resultant inhibition
of T-lymphocyte helper type 1 (Th1) activity,
for the few (if, indeed, any at all) lymphocytes
that may have escaped thymic involution with
adequate specificity for epitopes on the surface of
H. pylori, is likely to result in a further dampened
immune response against this pathogen.62
A co-ordinated and effective immune response is
also vital for the body to effectively eliminate cells
recognized to be undergoing malignant change.63
This ‘tumour surveillance’ and ‘tumour immunity’
is likely to be severely dampened in older adults,
not least if the antigen receptor pool is diminished
in overall sensitivity as a result of oligoclonal
expansion. New techniques seeking to utilize the
immune system to target cancer cells, as part
of the ‘tumour immunotherapy’ field, are thus
likely to need refining and rethinking in the older
populations as a result of the decline in the immune
system’s function. It is important to note, however,
that epidemiological evidence indicating a role for
the immune system in targeting its own cancer cells
has not, as yet, been adequately supported by direct
evidence.
The consequences of immunosenescence are
severe in terms of allowing pathogenic micro-
organisms capable of triggering an inflammatory
response to take hold in the body. The decline
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in NK cells, though no example is illustrated,
is also beneficial to viral agents. Yet this is
a paradoxical situation. If the responses of
immune cells are dampened with age, how
then would such pathogens trigger potentially
carcinogenic inflammation? The answer to this
question potentially lies in the smouldering,
ineffective, cytokine-orchestrated inflammatory
state of inflammaging.
Cytokine-driven carcinogenic inflammation
A chronic low-level state of inflammation has
been identified in older populations and is
associated with the induction of a PCM/CM.14
This chronic inflammation is thought to stem from
low-level persistent infection, chronic exposure
to toxic agents or aberrant responses against
the body’s own antigenic determinants and is
co-ordinated by a cascade of cytokine–cellular
interactions.28,64 Although inflammation is thus
thought to be deleterious in the state that
characterizes inflammaging, when acute it is
essentially a protective process, usually occurring
in response to pathogenic insult.
Tumour necrosis factor-α and cyclo-oxygenase
Foremost in the pro-inflammatory cytokine
hierarchy is TNF-α, which is associated pre-
dominantly with the induction of inflammation
and neoplastic modulation.65 This cytokine is
typically released from macrophages, though
more recent evidence has highlighted a role for
T-lymphocytes in its production.66 It is thought
to encourage malignancy through triggering DNA
damage and angiogenesis,65 and by inducing the
anti-apoptotic NF-κB transcription pathway.67,68
The effects of TNF-α are, however, notably
pleiotrophic, and very high concentrations of this
cytokine are associated with an anti-neoplastic
response.69
TNF-α is significantly up-regulated during
ageing,70,71 although tissue-specific contradictions
are present in the literature. One such discrepancy
is the skin; cutaneous macrophages have been
noted to synthesize and release decreasing
quantities of TNF-α as an individual ages,54
as previously stated. This would imply a direct
role for TNF-α in inducing skin cancer (as it
would no longer be found in protective high
concentrations) but may also indirectly influence
carcinogenesis. This, one theorizes, would occur
through reduced cutaneous T-lymphocyte helper
type 2 (Th2) recruitment and a resultant decrease
in immunosurveillance; thus allowing pathogens to
colonize the skin and cause chronic infection. It is
also known that the susceptibility of macrophages
to age-related oxidative stress is reduced amongst
centenarians,70 potentially leading to protect-
ively increased TNF-α production amongst this
populace.
A study by Bruunsgaard et al.72 assisted in
simplifying the controversy surrounding TNF-α
levels present in older individuals by inducing
infection and identifying the cytokine response.
It was found that as age increases, acute TNF-α
production is likely to be reduced, whilst more
chronic release is greater than that seen in younger
individuals. Chronic low-level TNF-α production
in the elderly will not only directly increase
malignancy but will, intriguingly, interact with
COX to indirectly increase malignant potential.14
These interactions commonly involve chronically
raised TNF-α, stimulating the oxidative cytotoxic
cascade, thus forming nitric oxide (NO).73 This
NO then interacts with cytotoxic perinitrite
(ONOO−) and activates cyclo-oxygenase type 2
(COX-2).74
COX-2 produces inflammatory mediator
prostaglandins and is thus thought to promote cell
proliferation, stimulate angiogenesis and inhibit
apoptosis as a result.75 Interesting epidemiological
studies support this hypothesis by indicating that
bowel cancer risk (the development of which is
closely linked with pervasive inflammation) is
decreased amongst patients prescribed NSAIDs
(non-steroidal anti-inflammatory drugs; these
inhibit the COX enzymes irreversibly or reversibly,
depending on the particular formulation).76
Of intrigue, therefore, is evidence from the
centenarian population that indicates adaptation
to lower inflammatory cytokine levels, thus
reducing the likelihood of cancer development.
COX alleles known to be pro-inflammatory are at
much lower incidence amongst this population;77
for example, the –308A TNF-α SNP single-
nucleotide polymorphism (SNP), associated with
decreased longevity and increased inflammation
when compared with the –308G variant,78 is at
remarkably low incidence amongst both those who
live to a greater age and those in low-cancer
incidence populations.77,78
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Highs and lows: interleukin-6 and interleukin-10
Single base changes in the genetic code capable
of providing adaptation to a reduced likelihood
of cancer development are thus evident. Such
genetic modulation appears consistent throughout
the many cytokines associated with provoking
the chronic, low-grade inflammation seen during
ageing. Interleukin-6 (IL-6) is such an example.
It is capable of acting both to induce cellular
growth and to inhibit apoptosis,79,80 with several
studies even indicating its potential use as a
general prognostic factor in cancer.80 This cytokine
has for some time also been associated with
the induction of metastases through the up-
regulation of endothelial adhesion molecules and
by increasing VEGF production.81,82
Importantly, the polymorphic –174CG base
pair of the IL-6 gene may be changed to
provide beneficial adaptation in a select few.83 If
homozygous for the G allele, subjects are known
to produce dramatically increased quantities of
IL-6 with ageing, increasing cancer incidence
amongst these individuals. Centenarians and
several population groups with low cancer
incidence have, however, been found to feature
this allele in exceptionally low incidence whilst
polymorphisms providing high quantities of the
anti-inflammatory cytokine interleukin-10 (IL-10)
are far more prevalent than in the general
population.77 Also of relevance in this context
are polymorphic changes controlling eosinophil
production, since rising eosinophil number is
associated with increased IL-6 concentration in old
age.51
Interleukin-6 is also known to increase
the production of C-reactive protein (CRP),84
concentrations of which rise during ageing.85
Intriguingly, CRP is used as a surrogate marker
of inflammatory activity,85 providing evidence
of inflammaging, but raised levels have also
been associated with the development of bowel
cancer,86 further supporting the link between
ageing, inflammation and cancer.
Toll-like receptors
Whilst TNF-α, COX, IL-6 and IL-10 are the
principal cytokines to have been strictly associated
with ageing, the Toll-like receptor (TLR) family of
proteins also appears to be important in age-related
cancer pathogenesis.87 This is likely to be due to
their role in ‘detecting’ the danger signals that
fuel the pro-inflammatory cytokine pool. There
are many polymorphisms in the TLR genetic code
and numerous examples of these are associated
with reduced cancer risk, potentially through
creating less specific TLRs and thereby reducing
the quantity of pro-inflammatory cytokine triggers
‘seen’ by the immune system.87,88 This raises
the possibility that, whilst certain populaces may
be less efficient at eradicating infective micro-
organisms, they may be conversely adapted to a
longer life free of cancer.
Interleukin-2: paradoxical change?
Concentrations of interleukin-2 (IL-2) are thought
to decrease during ageing,85 which may assist in
reducingmetastatic spread by limiting angiogenesis
(IL-2 is a potent stimulator of VEGF production,
indirectly eliciting angiogenesis as a result).89,90
The decrease in production of this cytokine occurs
predominantly as a result of changes in CD4+
T-cells and it is important to note that IL-2 is
crucial for foxp3+ Treg peripheral expansion.62
This appears paradoxical in the light of the age-
related increase in Treg activity,62 and this research
conundrum requires further elucidation.
Conclusion
The immune system is complex and dynamic,
shifting as a whole to unleash a host of
pathological changes in older individuals. Cancer
arises principally as a result of an accumulation of
genetic change; but the role of the ageing immune
system in both the progression and regression of
cancers is not to be ignored.
Elegant experiments have demonstrated the
ability of the immune system to modulate a
cell’s malignant potential through modifying its
immediate environment. For example, whilst the
deteriorating ability of the body to fight off
infection with increasing age is likely to assist in
the seating of oncogenic micro-organisms within
the body, the inflammatory cytokine soup created
as a result demonstrates the body’s own ability to
create a pro-cancer micro-environment. So poor
does the immune system’s function become with
increasing age that tumour surveillance is also
severely compromised.
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This role for the immune system in controlling
cancer pathogenesis is reflected not just by the
deceleration and plateau of cancer incidence rates
in the very latest stages of life, but by the
exceptionally low cancer incidence rates present in
some older populations and by the many cancers
associated with pathogenic infection and chronic
inflammation. Mapping the genetic changes that
can adapt the immune system to favour against
cancer development in older adults may provide
new therapeutic avenues that result in better
protection against this complex disease.
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